Dramatic Response to Tezepelumab as an Initial Biologic Agent for Refractory Asthma Associated with Type 2 and Non-type 2 Traits

A 74-year-old Japanese woman presented with a 45-year history of refractory asthma. She had been treated with inhaled corticosteroids, a long-acting β2-agonist, and a long-acting muscarinic antagonist for 6 months. She also had a repeated viral infection. Her condition had been characterized as a re...

Full description

Saved in:
Bibliographic Details
Published inActa medica Okayama Vol. 77; no. 6; p. 671
Main Authors Minami, Daisuke, Hosoya, Takeshi, Hosoya, Masaharu, Nagano, Akichika, Nakajima, Yasuhiro, Miyahara, Nobuaki, Kanehiro, Arihiko
Format Journal Article
LanguageEnglish
Published Japan 01.12.2023
Subjects
non-type 2
severe asthma
eosinophilic
biologic agent
tezepelumab
Online AccessGet full text

Cover

More Information
Summary:A 74-year-old Japanese woman presented with a 45-year history of refractory asthma. She had been treated with inhaled corticosteroids, a long-acting β2-agonist, and a long-acting muscarinic antagonist for 6 months. She also had a repeated viral infection. Her condition had been characterized as a refractory asthma associated with type 2 and non-type 2 traits. We began treatment with tezepelumab. The control of the patient's asthma symptoms and quality of life improved greatly within 1 month (changes in eosinophil count from 748 to 96 /μL, in FeNO from 32 to 17 ppb, in the Asthma Quality of Life Questionnaire score from 3.59 to 6.68, and in the Asthma Control Test score from 13 to 23). Tezepelumab was effective as an initial biologic agent for a patient with refractory asthma associated with type 2 and non-type 2 traits.
ISSN:0386-300X
DOI:10.18926/amo/66161